New Cervical Cancer Guideline Addresses Global Resource Disparities

For immediate release
May 25, 2016
Contact
Lada Krilov
571-483-1377
lada.krilov@asco.org

ALEXANDRIA, Va. - The American Society of Clinical Oncology (ASCO) today issued its first clinical practice guideline on invasive cervical cancer. This resource-stratified guideline is the first of its kind from ASCO, offering treatment recommendations tailored to resource availability.

Access to cervical cancer care varies between regions of the world, both among and within countries. Lower resource settings tend to have limited or no cervical cancer screening programs. As a result, women often have advanced cervical cancer at diagnosis, which requires treatments that may not be readily available in these areas.

"Even though cervical cancer is largely preventable, a quarter of a million women die of this disease every year globally. The vast majority of those deaths occur in less developed regions of the world, such as South-East Asia, the Western Pacific, India and Africa," said Linus Chuang, MD, MS, co-chair of the ASCO Expert Panel that developed the guideline, and a gynecologic oncologist and a professor of obstetrics, gynecology and reproductive science at the Icahn School of Medicine at Mount Sinai in New York, NY. "In those regions, access to pathology services, skilled surgeons, radiation machines, brachytherapy, chemotherapy and palliative care may all be constrained."

This guideline provides evidence-based recommendations for four resource tiers: basic, limited, enhanced and maximal. For each setting, and for each stage of cervical cancer, the guideline recommends optimal therapy and palliative care.

"Regardless of resources, health care providers should always strive to deliver the highest level of care to all women with cervical cancer," said Jonathan S. Berek, MD, MMS, co-chair of the ASCO Expert Panel that developed the guideline, and professor and chair of obstetrics, gynecology - gynecologic oncology at Stanford University School of Medicine in Stanford, CA. "This guideline is
The guideline recommendations were developed by a multidisciplinary panel of experts in cancer control; gynecologic, medical and radiation oncology; health economics; obstetrics and gynecology; and palliative care. The panel included experts from the United States, Spain, Mexico, Turkey, Canada, Argentina, Zambia, Uganda, South Korea, China and India, as well as a cancer survivor.

The panel conducted a systematic review of medical literature published from 1966 to 2015, and reviewed existing guidelines and cost-effective analyses. Recommendations were made based on evidence from literature and/or Panel expertise. All recommendations reflect formal expert consensus.

Key guideline recommendations:

- In basic settings where patients cannot be treated with radiation therapy, extrafascial hysterectomy either alone or after neoadjuvant chemotherapy may be an option for women with stage IA1 to IVA cervical cancer.
- Concurrent radiotherapy and chemotherapy is standard in enhanced and maximal settings for women with stage IB to IVA disease. The panel stresses the addition of low-dose chemotherapy during radiotherapy, but not at the cost of delaying radiation therapy if chemotherapy is not available in limited settings.
- In limited resource settings where there is no brachytherapy, the ASCO Expert Panel recommends extrafascial hysterectomy or its modification for women who have residual tumor two to three months after concurrent chemoradiotherapy and additional boost.
- If the resources are available and the patient cannot receive treatment with curative intent, palliative radiotherapy should be used to relieve symptoms of pain and bleeding.
- Where resources are constrained, single- or short-course radiotherapy schemes can be used with re-treatments if feasible for persistent or recurrent symptoms.
- For patients with stage IV or recurrent cervical cancer, single-agent chemotherapy (carboplatin or cisplatin) is recommended in basic settings.
- Concurrent radiotherapy and chemotherapy followed by brachytherapy is standard in enhanced and maximal settings for women with stage IB to IVA disease.

"At least two-thirds of cervical cancer deaths occur in women who hadn't been screened regularly. If we improved screening and HPV vaccination around the world, we might be able to substantially decrease the mortality from cervical cancer," said Dr. Berek. ASCO will address cervical cancer prevention and screening in two separate resource-stratified guidelines to be published later this year.

This guideline has been endorsed by the Society of Gynecologic Oncology and the Gynecologic Cancer Intergroup.

Related ASCO materials include:

- American Society of Clinical Oncology Statement: Human Papillomavirus Vaccination for Cancer Prevention
- Guide to Cervical Cancer
- Making Decisions About Cancer Treatment

ASCO encourages feedback on its guidelines from oncologists, practitioners, and patients through the ASCO Guidelines Wiki at www.asco.org/guidelineswiki.

###

About the Journal of Clinical Oncology:
The Journal of Clinical Oncology (JCO), the flagship journal of the American Society of Clinical Oncology, is a leader in reach, readership, impact, and influence. With a focus on significant clinical oncology research, JCO publishes over 1,000 articles in 36 issues a year.

About ASCO:

Founded in 1964, the American Society of Clinical Oncology (ASCO) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents more than 40,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at www.ASCO.org, explore patient education resources at www.Cancer.Net, and follow us on Facebook, Twitter, LinkedIn, and YouTube.